Edition:
United States

Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

209.47USD
19 Jul 2019
Change (% chg)

$-4.95 (-2.31%)
Prev Close
$214.42
Open
$214.71
Day's High
$215.97
Day's Low
$209.23
Volume
113,650
Avg. Vol
61,590
52-wk High
$217.11
52-wk Low
$132.75

Latest Key Developments (Source: Significant Developments)

Bio-Techne Receives Approval To Offer The Exodx Prostate Intelliscore Test In New York State
Thursday, 13 Jun 2019 04:35pm EDT 

June 13 (Reuters) - Bio-Techne Corp ::BIO-TECHNE RECEIVES APPROVAL TO OFFER THE EXODX™ PROSTATE INTELLISCORE™ (EPI) TEST IN NEW YORK STATE.BIO-TECHNE - RECEIVED CLINICAL LABORATORY PERMIT FROM NEW YORK STATE DEPARTMENT. OF HEALTH TO PROVIDE ITS EXODX PROSTATE INTELLISCORE TEST IN NEW YORK.  Full Article

Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For Mrna Ish Tissue Analysis
Monday, 6 May 2019 07:00am EDT 

May 6 (Reuters) - Roche Holding AG ::ROCHE EXPANDS PARTNERSHIP WITH BIO-TECHNE TO OFFER DRUG DISCOVERY RESEARCHERS NEW CHROMOGENIC DETECTION OPTIONS FOR MRNA ISH TISSUE ANALYSIS.ROCHE - EXPANDED ITS PARTNERSHIP WITH BIO-TECHNE.ROCHE - NEW ROCHE KITS INCLUDE DISCOVERY MRNA PURPLE HRP DETECTION KIT (RUO) AND DISCOVERY MRNA TEAL HRP DETECTION KIT.  Full Article

Bio-Techne Posts Q3 Adjusted Earnings Per Share of $1.21
Tuesday, 30 Apr 2019 06:30am EDT 

April 30 (Reuters) - Bio-Techne Corp ::BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2019 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $1.21.Q3 GAAP EARNINGS PER SHARE $1.15.Q3 REVENUE $184.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $182.9 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.14 -- REFINITIV IBES DATA.  Full Article

Bio-Techne Q2 GAAP Earnings Per Share $1.29
Tuesday, 6 Feb 2018 07:00am EST 

Bio-Techne Corp ::BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2018 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $1.02.Q2 GAAP EARNINGS PER SHARE $1.29.Q2 SALES $154.2 MILLION.QTRLY GAAP EPS SAW A ONE-TIME BENEFIT OF $0.94 FROM TAX REFORM.  Full Article

Bio-Techne Acquires Atlanta Biologicals Inc
Tuesday, 2 Jan 2018 05:01pm EST 

Jan 2 (Reuters) - Bio-Techne Corp ::BIO-TECHNE ACQUIRES ATLANTA BIOLOGICALS INC.BIO-TECHNE CORP - ‍TRANSACTION IS FINANCED THROUGH AVAILABLE CASH ON HAND​.BIO-TECHNE - DEAL EXPECTED TO BE SLIGHTLY ACCRETIVE TO ADJUSTED EARNINGS PER SHARE FOR FISCAL YEAR 2018.  Full Article

Bio-Techne releases Q1 adjusted earnings per share $0.90
Tuesday, 31 Oct 2017 07:35am EDT 

Oct 31 (Reuters) - Bio-Techne Corp :Bio-Techne releases first quarter fiscal 2018 results.Q1 adjusted earnings per share $0.90.Q1 GAAP earnings per share $0.42.Q1 sales $144.6 million versus I/B/E/S view $142.9 million.Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S.  Full Article

Bio-Techne releases serological assay to detect Zika virus infections
Wednesday, 6 Sep 2017 05:40pm EDT 

Sept 6 (Reuters) - Bio-techne Corp :Bio-Techne releases a highly sensitive and specific serological assay to detect Zika virus infections.‍R&D systems - release of new rapid, solid phase, ELISA designed to measure anti-zika virus immunoglobulin g (IgG) antibodies in human serum​.Research and Development Systems-ELISA kit can be used to detect prior infections, determine whether Zika virus may be linked to subsequent neurological disorders/fetal abnormalities​.Research and Development Systems- in-house testing shows kit is "highly sensitive" to anti-Zika virus IgG, displays minimal cross-reactivity with dengue virus IgG antibodies​.  Full Article

Bio-Techne acquires Trevigen Inc
Tuesday, 5 Sep 2017 06:07pm EDT 

Sept 6 (Reuters) - Bio-techne Corp :Bio-Techne acquires Trevigen Inc.Bio-Techne Corp says transaction is financed through available cash on hand.Bio-Techne Corp - ‍Acquisition is expected to be accretive to Bio-Techne's adjusted earnings per share for its fiscal year 2018​​.Bio-Techne Corp - ‍Has acquired all of stock of Trevigen Inc for cash​.  Full Article

Bio-Techne Q4 adjusted earnings per share $1.09
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Bio-techne Corp :Bio-Techne releases fourth quarter fiscal 2017 results.Q4 adjusted earnings per share $1.09.Q4 gaap earnings per share $0.77.Q4 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.Q4 sales $156.6 million versus i/b/e/s view $150.1 million.  Full Article

BRIEF-Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For Mrna Ish Tissue Analysis

* ROCHE EXPANDS PARTNERSHIP WITH BIO-TECHNE TO OFFER DRUG DISCOVERY RESEARCHERS NEW CHROMOGENIC DETECTION OPTIONS FOR MRNA ISH TISSUE ANALYSIS